

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

FIRST NAMED INVENTOR APPLICATION NO. FILING DATE ATTORNEY DOCKET NO. CONFIRMATION NO. 12/04/2001 10/006,796 Eija Pirhonen 01942-00007 9843 EXAMINER 22910 7590 09/19/2005 BANNER & WITCOFF, LTD. YOUNG, MICAH PAUL 28 STATE STREET ART UNIT PAPER NUMBER 28th FLOOR BOSTON, MA 02109-9601 1618

DATE MAILED: 09/19/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

10/006,796	PIRHONEN ET AL.
Examiner	Art Unit
Micah-Paul Young	1618
appears on the cover sheet w	vith the correspondence address
DATE OF THIS COMMUN 1.136(a). In no event, however, may a	reply be timely filed NTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).
September 2004.	
his action is non-final.	
vance except for formal mat	tters, prosecution as to the merits is
r <i>Ex parte Quayle</i> , 1935 C.I	D. 11, 453 O.G. 213.
on.	
rawn from consideration.	
	•
d/or election requirement.	
ner.	
ccepted or b)☐ objected to	by the Examiner.
ne drawing(s) be held in abeya	nce. See 37 CFR 1.85(a).
ection is required if the drawing	g(s) is objected to. See 37 CFR 1.121(d).
Examiner. Note the attache	d Office Action or form PTO-152.
gn priority under 35 U.S.C.	§ 119(a)-(d) or (f).
ents have been received.	
	Application No.
	received in this National Stage
eau (PCT Rule 17.2(a)).	ŭ
st of the certified copies not	received.
•	
4) Interview	Summary (PTO-413)
Paper No	s)/Mail Date
98) 5) 🔲 Notice of	Informal Patent Application (PTO-152)
6) Other:	<u>_</u> .
	Examiner Micah-Paul Young PLY IS SET TO EXPIRE 3 M DATE OF THIS COMMUN 1.136(a). In no event, however, may a dot will apply and will expire SIX (6) MO total cause the application to become A tilling date of this communication, even if September 2004. Inis action is non-final. Vance except for formal main or Ex parte Quayle, 1935 C.I. Ton. Trawn from consideration. If or election requirement. If or election requirement. If or election is required if the drawing Examiner. Note the attached one drawing(s) be held in abeya tection is required if the drawing Examiner. Note the attached one priority under 35 U.S.C. Ints have been received. Ints have been received in A tiority documents have been the part of the certified copies not A) Interview Paper Not A)

Art Unit: 1618

DETAILED ACTION

Acknowledgment of Papers Received: Amendment/Response dated 9/24/04.

Claim Rejections - 35 USC § 103

- 1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- 3. Claims 1-17 are rejected under 35 U.S.C. 103(a) as being unpatentable over the disclosures of Dunn et al (WO 91/01126 hereafter '126).
- 4. Dunn et al discloses biodegradable system for regenerating the periodontium. The implant comprises a polymeric matrix along with various other solvents and components. The polymers are selected from polylactides, polyglcolides, and polyamides (pg. 8, lin. 23 38). N-methyl-2-pyrrolidone is recited as a solvent in the system (pg. 9, lin. 23 25). Once implanted/injected into the body the solvents dissipate leaving a more rigid polymer comprising a porous polymer with bioactive agents such as growth hormones and/or antimicrobial agents lodged within the polymeric matrix (pg. 11, lin. 13 pg. 12, lin. 8). Since claims 1-8 are drawn to a product is irrelevant the order in which the product is made. Claims 6 and 7 are deemed product-by-process claims and do not impart patentability on the invention.
- 5. As discussed above Dunn et al discloses many of the essential elements of the invention. Dunn discloses a biodegradable implant used for rebuilding tissue, where the

Art Unit: 1618

implant comprises N-methyl-2-pyrrolidone, which dissipates from the implant upon placement in the body. What is lacking however is an explicit disclosure to the differing order of manufacture recited by applicant. It is the position of the examiner that theses claims are non critical to the patentability of the invention. Dunn presents an identical product made with identical components, used for the same purpose of regenerating tissue. The Office does not have the facilities for examining and comparing applicant's product with the product of the prior art in order to establish that the product of the prior art does not possess the same material structural and functional characteristics of the claimed product. In the absence of evidence to the contrary, the burden is upon the applicant to prove that the claimed products are functionally different than those taught by the prior art and to establish patentable differences. *See Ex parte Phillips*, 28 U.S.P.Q.2d 1302, 1303 (PTO Bd. Pat. App. & Int. 1993), *Ex parte Gray*, 10 USPQ2d 1922, 1923 (PTO Bd. Pat. App. & Int.) and *In re Best*, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977).

6. It would be within the level of skill in the art to manipulate the order of the procedure, in order to determine the most effective manufacturing method. This can be accomplished through routine experimentation in the art. With this in mind, it would have been obvious to one of ordinary skill in the art to follow the teachings and suggestions of Dunn in order to rebuild periodontal tissue after surgery. A skilled artisan would have expected to attain a porous, biodegradable implant useful in rebuilding periodontal tissue after dental surgery. The bioactive agents in the implant would help treat any possible infections, during the healing process.

Art Unit: 1618

Response to Arguments

Page 4

7. Applicant's arguments filed 9/29/04 have been fully considered but they are not persuasive. Applicant argues elements, which do not impart patentability on the claims.

8. Applicant argues that since the implant of the instant claims is solid before entering the body it is distinct over the prior art, which is a liquid before implantation. However it is the position of the Examiner that this limitation is drawn to process step and renders the product claims product-by-process claims, which would not distinguish them over identical products of the prior art. Further applicant has yet to provide a patentable distinction other than the prior body form of the implant. The claims are drawn to the implant in the body, and in that respect the implant of Dunn is identical to that of the instant claims. The Dunn reference teaches identical polymers and identical plasticizers used to create a product within the same field of biodegradable periodontal implants. Burden is shifted to applicant to provide a patentable distinction between the claims of the instant invention and the teachings of the Dunn reference. Until such evidence of unexpected results and patentable distinction is presented the claims remain obviated by the art.

Conclusion

9. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not

Art Unit: 1618

mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Micah-Paul Young whose telephone number is 571-272-0608. The examiner can normally be reached on M-F 7:00-4:30 every other Monday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K. Page can be reached on 571-272-0602. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Micah-Paul Young Examiner Art Unit 1618

WK MP Young

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

Page 5